Toxicology and Applied Pharmacology 2015-08-15

Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action.

Maria-Christina Scherzberg, Andreas Kiehl, Aleksandra Zivkovic, Holger Stark, Jürgen Stein, Robert Fürst, Dieter Steinhilber, Sandra Ulrich-Rückert

Index: Toxicol. Appl. Pharmacol. 287 , 67-76, (2015)

Full Text: HTML

Abstract

(Z)-3,5,4'-Trimethoxystilbene (Z-TMS) is a resveratrol analog with increased antiproliferative activity towards a number of cancer cell lines compared to resveratrol, which has been shown to inhibit tubulin polymerization in vitro. The purpose of this study was to investigate if Z-TMS still shows potential for the prevention of metabolic diseases as known for resveratrol. Cell growth inhibition was determined with IC50 values for Z-TMS between 0.115μM and 0.473μM (resveratrol: 110.7μM to 190.2μM). Flow cytometric analysis revealed a G2/M arrest after Z-TMS treatment, whereas resveratrol caused S phase arrest. Furthermore, Z-TMS was shown to impair microtubule polymerization. Beneficial effects on lipid accumulation were observed for resveratrol, but not for Z-TMS in an in vitro steatosis model. (E)-Resveratrol was confirmed to elevate cAMP levels, and knockdown of AMPK attenuated the antiproliferative activity, while Z-TMS did not show significant effects in these experiments. SIRT1 and AMPK activities were further measured indirectly via induction of the target gene small heterodimer partner (SHP). Thereby, (E)-resveratrol, but not Z-TMS, showed potent induction of SHP mRNA levels in an AMPK- and SIRT1-dependent manner, as confirmed by knockdown experiments. We provide evidence that Z-TMS does not show beneficial metabolic effects, probably due to loss of activity towards resveratrol target genes. Moreover, our data support previous findings that Z-TMS acts as an inhibitor of tubulin polymerization. These findings confirm that the methylation of resveratrol leads to profound changes in the mode of action, which should be taken into consideration when conducting lead structure optimization approaches. Copyright © 2015 Elsevier Inc. All rights reserved.

Related Compounds

Structure Name/CAS No. Articles
sodiumborohydride Structure sodiumborohydride
CAS:16940-66-2
PIPES Structure PIPES
CAS:5625-37-6
Sodium Oleate Structure Sodium Oleate
CAS:143-19-1
Magnesium choride Structure Magnesium choride
CAS:7786-30-3
Palmitic acid sodium Structure Palmitic acid sodium
CAS:408-35-5
DOTAP Transfection Reagent Structure DOTAP Transfection Reagent
CAS:144189-73-1